Get the Stockscreener App
3.56
2.47%
-0.09
After Hours:
3.60
0.04
+1.12%
Ataibeckley Inc stock is traded at $3.56, with a volume of 5.21M.
It is down -2.47% in the last 24 hours and down -9.87% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$3.65
Open:
$3.65
24h Volume:
5.21M
Relative Volume:
1.24
Market Cap:
$1.29B
Revenue:
$3.06M
Net Income/Loss:
$-141.62M
P/E Ratio:
-4.8416
EPS:
-0.7353
Net Cash Flow:
$-78.67M
1W Performance:
-12.32%
1M Performance:
-9.87%
6M Performance:
-24.58%
1Y Performance:
+163.70%
1-Day Range:
$3.55
$3.695
1-Week Range:
$3.55
$4.08
52-Week Range:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.56 | 1.33B | 3.06M | -141.62M | -78.67M | -0.7353 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility - simplywall.st
AtaiBeckley publishes Phase 2a data for depression treatment By Investing.com - Investing.com Canada
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Small cap wrap: AtaiBeckley, New Era Energy & Digital, Standard Uranium, Namibia Critical Metals… - Proactive financial news
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - Seeking Alpha
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 - Proactive financial news
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation - Bitget
AtaiBeckley publishes Phase 2a data for depression treatment - Investing.com India
AtaiBeckley Inc. Publishes Positive Phase 2a Study Results of BPL-003 for Treatment-Resistant Depression in Journal of Psychopharmacology - Quiver Quantitative
Single-dose nasal spray eases treatment-resistant depression in 12-patient trial - Stock Titan
Atai Beckley NV (ATAI) is a buy on mental therapeutics opportunities - MSN
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
symbol__ Stock Quote Price and Forecast - CNN
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria
Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com
H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 - Investing.com South Africa
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance
AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Atai Beckley N.V. (ATAI) and Artivion (AORT) - The Globe and Mail
Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting - TipRanks
AtaiBeckley Inc. Advances BPL-003 toward Phase 3 Trials for Treatment-Resistant Depression Following Positive Phase 2b Results - Quiver Quantitative
AtaiBeckley nasal spray for hard-to-treat depression eyes 2026 trials - Stock Titan
Assessing Atai (ATAI) Valuation After FDA Backing For BPL-003 And Positive EMP-01 Trial Results - simplywall.st
AtaiBeckley Exploring Potential Sale, Partnership for Psychedelic Drug Candidate - marketscreener.com
Atai Life Sciences Stock Poised for Gains Amid New FDA Trials Approval - timothysykes.com
FDA Supports AtaiBeckley’s New Depression Treatment Trials - StocksToTrade
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
AtaiBeckley’s FDA Backing And Trial Data Reframe Mental Health Upside And Risk - Yahoo Finance
4 Analysts Have This To Say About AtaiBeckley - Benzinga
AtaiBeckley Files For Mixed Shelf Offering - TradingView
Atai Beckley Inc (ATAI) has filed documents with the U.S. Securities and Exchange Commission (SEC) to allow selling shareholders to resell up to 74.3 million ordinary shares. - Bitget
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg - MSN
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 - Insider Monkey
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
AtaiBeckley Advances Key Depression And Anxiety Programs As Losses Mount - Sahm
Ataibeckley (ATAI) to initiate phase 3 depression study following positive FDA meeting - MSN
AtaiBeckley weighing options for psychedelic drug (ATAI:NASDAQ) - Seeking Alpha
Atai Beckley is said to explore options for main psychedelic drugBloomberg News - marketscreener.com
AtaiBeckley Is Said To Explore Options For Main Psychedelic Drug- Bloomberg News - TradingView
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):